TESTING (final results) (2022) — Trial Summary
TESTING (final results) (2022): Final report of the TESTING trial (n=503) of oral methylprednisolone versus placebo in IgA nephropathy with proteinuria ≥1 g/day. The first 262 participants were randomized under the full-dose regimen (0.6–0.8 mg/kg/day; 136 methylprednisolone, 126 placebo); after exc
References
- Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327(19):1888-1898.